Metabolic bariatric surgery as a therapeutic option for patients with type 2 diabetes: A meta‐analysis and network meta‐analysis of randomized controlled trials
- 5 June 2023
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 25 (8) , 2362-2373
Abstract
Aim: To compare different types of metabolic surgery with non‐surgical therapy for the treatment of type 2 diabetes (T2D). Methods: The present network meta‐analysis (NMA) includes randomized clinical trials (duration ≥ 52 weeks) comparing different surgery techniques with non‐surgical therapy in diabetes patients. The primary endpoints were endpoint HbA1c, body mass index (BMI) and diabetes remission. The secondary endpoints included fasting plasma glucose, lipid profile, blood pressure, arterial hypertension and dyslipidaemia remission, quality of life and surgical adverse events. Indirect comparisons of different types of surgery were performed by NMA. Mean and 95% confidence intervals for continuous variables, and the Mantel–Haenzel odds ratio for categorial variables, were calculated. Results: The types of surgical procedure included laparoscopic adjustable gastric banding, Roux‐en‐Y gastric bypass (RYGB), sleeve gastrectomy (SG), bilio‐pancreatic diversion (BPD), greater curvature plication (GCP), one‐anastomosis gastric bypass (OAGB) and Duodeno–Jejunal bypass. Thirty‐six trials were included. Metabolic bariatric surgery (MBS) was associated with a significantly higher reduction of HbA1c, diabetes remission and BMI compared with medical therapy. In the NMA, a significant reduction of HbA1c was observed with OAGB and SG. Complete diabetes remission significantly increased with all surgical procedures in comparison with non‐surgical therapy, except for GCP. In addition, only BPD, RYGB and OAGB were associated with a significant reduction of BMI. Conclusions: MBS is an effective option for the treatment of T2D in patients with obesity. Further long‐term trials of appropriate quality are needed for assessing the risk–benefit ratio in some patient cohorts, such as those with a BMI of less than 35 kg/m 2 and aged older than 65 years.Keywords
This publication has 41 references indexed in Scilit:
- The statistical significance of randomized controlled trial results is frequently fragile: a case for a Fragility IndexJournal of Clinical Epidemiology, 2014
- Laparoscopic gastric plication versus mini-gastric bypass surgery in the treatment of morbid obesity: A randomized clinical trialSurgery for Obesity and Related Diseases, 2013
- Effect of laparoscopic Roux-en-Y gastric bypass surgery on type 2 diabetes mellitus with hypertension: A randomized controlled trialDiabetes Research and Clinical Practice, 2013
- GRADE guidelines: 12. Preparing Summary of Findings tables—binary outcomesJournal of Clinical Epidemiology, 2013
- Prospective randomized clinical trial of laparoscopic sleeve gastrectomy versus open Roux-en-Y gastric bypass for the management of patients with morbid obesity.Videosurgery and Other Miniinvasive Techniques, 2012
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendationsBMJ, 2008
- Adjustable Gastric Banding and Conventional Therapy for Type 2 DiabetesJAMA, 2008
- Roux-en-Y Gastric Bypass versus a Variant of Biliopancreatic Diversion in a Non-Superobese Population: Prospective Comparison of the Efficacy and the Incidence of Metabolic DeficienciesObesity Surgery, 2006
- The Relationship between Health‐Related Quality of Life and Weight LossObesity Research, 2001
- The rand 36‐item health survey 1.0Health Economics, 1993